Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: A multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b

Journal of Viral Hepatitis

Volumn 13, Issue 12, 2006, Pages 811-820

  Abergel, A ^a,k   Hezode, C ^b   Leroy, V ^c   Barange, K ^d   Bronowicki, J P ^e   Tran, A ^f   Alric, L ^d   Castera, L ^g,k   Bernard, P H ^h   Henquell, C ⁱ   Lafeuille, H ⁱ   Ughetto, S ^a   Darcha, C ^a   Chevallier, M ^j   Martineau, N ^a   Dubost, S ^a   Randl, K ^a   Dhumeaux, D ^b   Bommelaer, G ^a   Bonny, C ^a   Beaugrand, Michel ^k   Hézode, Christophe ^k   Dhumeaux, Daniel ^k   Grangé, Jean Didier ^k   Amiot, Xavier ^k   Feray, Cyrille ^k   Samuel, Didier ^k   Oberti, Frédéric ^k   Calès, Paul ^k   Arpurt, Jean Pierre ^k   Berton, Isabelle ^k   Bresson Hadni, Solange ^k   Bernard, Pierre Henri ^k   Fontanges, Thierry ^k   Nousbaum, Jean Baptiste ^k   Bommelaer, Gilles ^k   Bonny, Corinne ^k   Randl, Karine ^k   Leroy, Vincent ^k   Zarski, Jean Pierre ^k   Doll, Jacques ^k   Blanchi, Alain ^k   Bour, Bernard ^k   Canva, Valérie ^k   Paris, Jean Claude ^k   Loustaud Ratti, Véronique ^k   Mion, François ^l   Bourlière, Marc ^k   Portal, Isabelle ^k   Raabe, Jean Jacques ^k   Grobost, Olivier ^k   Larrey, Dominique ^k   Bronowicki, Jean Pierre ^k   Longo, Fabrice ^k   Tran, Albert ^k   Raffanel, C ^k   Ahmed, Si Nafa Si ^k   Causse, Xavier ^k   De Ledinghen, Victor ^k   Couzigou, Patrice ^k   Lévy, Stéphane ^k   Thieffin, Gérard ^k   Melin, Pascal ^k   Habersetzer, François ^k   Vetter, Denis ^k   Barange, Karl ^k   Alric, Laurent ^k   Desmorat, Hervé ^k   Bacq, Yannick ^k   Flamenbaum, Michel ^m   Cassan, Philippe ^m   more..

^a HÔTEL DIEU   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d CHU PURPAN   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g HÔPITAL JEAN VERDIER   (France)

^h HÔPITAL SAINT ANDRÉ   (France)

ⁱ ONERA   (France)

^j Institut Merieux   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l Assistance Publique Hôpitaux de Paris   (France)

^m NONE

more..

Author keywords

Cirrhosis; Hepatitis C; Peginterferon; Randomized trial; Ribavirin; Treatment

Indexed keywords

BENZODIAZEPINE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DRUG EFFICACY; ENDOCRINE DISEASE; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDE; THROMBOCYTE; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; VIREMIA;

EID: 33751009135     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00768.x     Document Type: Article

References (20)

1. Fattovitch G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
2. Benvegnu L, Gias M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-749.
3. Bedossa P, Poynard T, for the French METAVIR group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-293.
4. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
5. Fried M, Shiffman M, Reddy R et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
6. Hadziyannis S, Sette H, Morgan T et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 370-381.
7. Strader D, Wright T, Thomas D, Seeff L. Diagnosis, management and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
8. Lindsay K, Trepo C, Heintges T et al. A randomized, doubleblind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
9. McHutchinson J, Manns M, Poynard T et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
10. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
11. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
12. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: signifi-cance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609.
13. Harrison SA, Brunt EM, Qazi RA et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 604-609.
14. Bruno S, Camma C, Di Marco V et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474-481.
15. Shiffman M, Di Bisceglie A, Lindsay K et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023.
16. Peck-Radosavljevic M, Wichlas M, Homonick-Kraml M et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alfa. Gastroenterology 2002; 123: 141-151.
17. Dietrich D, Spivak J. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-541.
18. Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
19. Reddy K, Wright T, Pockros P et al. Efficacy and safety of Pegylated (40-Kd) Interferon alfa-2a compared with Interferon alfa-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.
20. Pockros P, Carithers R, Desmond P et al. Efficacy and safety of two doses regimens of Peginterferon alfa-2a compared with Interferon alfa-2a in chronic hepatitis C.: a multicentre randomized controlled trial. Am J Gastroenterol 2004; 99: 1298-1305.